BioSpace News Archive

Alterity Therapeutics today announced that it has received approval in Australia from the St. Vincent’s Hospital Melbourne Human Research Ethics Committee (HREC) to conduct the Phase 2 clinical trial of ATH434 for the treatment of individuals with Multiple System Atrophy (MSA).

Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced the upcoming poster presentation of new preclinical data for its lead therapeutic candidate, NTX-0250, which targets human papillomavirus (HPV)-driven cancers.

Poxel Announces Upcoming Presentation at the H.C. Wainwright 6th Annual NASH Investor Virtual Conference.

Hospital for Special Surgery, the world’s leading academic medical center focused on musculoskeletal health, and Lumoptik, Inc., a development stage medical device company with a first-in-kind proprietary light-based technology, announced a new collaborative relationship.

City of Hope, one of the largest cancer research and treatment organizations in the U.S., is proud to announce the inaugural Halloween for Hope, an event presented by the organization’s new Junior Board, featuring a soiree full of tricks and treats designed to enchant the entire family.

In an effort to create the pediatric research building of the future, Children’s Hospital of Philadelphia has joined forces with Gilbane Building Company, Pride Enterprises, and McKissack & McKissack to construct the Schuylkill Avenue Research Building.

NovelStem International Corp. (OTC Pink: NSTM), a development-stage company focused on the stem cell-based technology platform developed by 30%-owned, Israel-based NewStem Ltd., today announced that it has become an SEC-reporting company following the automatic effectiveness of its Form 10 registration statement filed August 2, 2022.

XBiotech announced the enrollment of the first patient in a multicenter, randomized clinical study for Natrunix in combination with trifluridine/tipiracil for the treatment of colorectal cancer.

Some of the most influential international medical experts, researchers and scientific minds participated in the fifth Bioelectronic Medicine Summit, “Bioelectronic Medicine: Today’s Tools, Tomorrow’s Therapies,” hosted by The Feinstein Institutes for Medical Research.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”) today presented promising pharmacodynamic, tolerability and preliminary functional efficacy data from the first three participants dosed in CANaspire, its Phase 1/2 clinical trial of BBP-812, an investigational intravenous (IV) adeno-associated virus serotype 9 (AAV9) gene therapy for the treatment of Canavan disease.